Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes? - Poll - MDSpire

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

  • By

  • January 29, 2026

  • 3 min

Share

Original Source(s)

Related Content